AKT1 and colorectal cancer: The results showed that MGO promotes tumor growth and metastasis and induces AKT activation through phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin 2 (mTORC2) and Hsp27 regulation, suggesting that MGO is a potential target to tackle EGFR-targeted therapy resistance in colorectal cancer.